Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications
-
IO Biotech Announces Participation in Upcoming December Investor Conferences
-
IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights
-
IO Biotech Announces Participation in Upcoming Investor Conferences
-
IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the SITC 2025 Annual Meeting
-
IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
-
IO Biotech Provides Update Following Pre-BLA Meeting with FDA
-
IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025
-
IO Biotech Announces Participation in Upcoming Investor Conferences
-
IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights